Mutters Nico T, Werner Guido, Tacconelli Evelina, Mischnik Alexander
Deutsches Zentrum für Infektionsforschung (DZIF) Heidelberg, Universitätsklinikum Heidelberg.
Fachgebiet Nosokomiale Infektionserreger und Antibiotikaresistenzen, Nationales Referenzzentrum für Staphylokokken und Enterokokken, Abt. Infektionskrankheiten, Robert Koch-Institut, Bereich Wernigerode.
Dtsch Med Wochenschr. 2015 Jan;140(1):42-5. doi: 10.1055/s-0040-100428. Epub 2015 Jan 12.
Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.
耐万古霉素肠球菌(VRE)引起的复杂性感染是一项治疗挑战,因为合适的治疗选择有限,且对现有药物的抗生素耐药性已被报道。VRE治疗中最常用的抗生素是利奈唑胺。替加环素是利奈唑胺的一种替代药物,然而,关于败血症或心内膜炎等严重感染的临床数据很少。一方面,达托霉素是一种选择,但另一方面在德国尚未被批准用于治疗肠球菌感染。本综述基于现有数据批判性地评估了上述抗生素在VRE治疗中的临床意义。